Vertex Pharmaceuticals, Incorporated (NASDAQ:VRTX) is scheduled to present at the 28th Annual JP Morgan Healthcare Conference on Tuesday, January 12. The company is set to begin speaking at 2:30 pm PT that afternoon. Investors may listen to a live webcast of the presentation on the company’s website, http://www.vrtx.com/. The webcast will be on the Events & Presentations page of the company’s website. A replay will be available on the site two hours following the conclusion of the presentation.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
Vertex Pharmaceuticals Incorporated (Vertex) is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Telaprevir, the Company’s principal drug candidate, is an oral hepatitis C protease inhibitor and an antiviral treatment in clinical development that targets hepatitis C virus (HCV) infection. As of December 31, 2008, Vertex was also developing, among other compounds, VX-770, a drug candidate for the treatment of patients with cystic fibrosis (CF). In March 2009, the Company completed its acquisition of ViroChem Pharma Inc., a company with two investigational HCV polymerase inhibitors in clinical development.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
